Pharma Veterans

New Information on Statins and Cardiovascular Risk – Asrar Qureshi’s Blog Post #1169 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1169 for Pharma Veterans. Pharma    Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Credit: Franki Frank Credit: Pavel Danilyuk Preamble This blog post is based on a recent article published in JAMA - Journal of American Medical Association. Link to article at the end. Rethinking Risk: How New Equations Could Alter Cardiovascular Prevention Cardiovascular disease remains a leading cause of death worldwide. Deciding who should receive preventive therapy, like statins, depends heavily on risk estimation models. For years, clinicians have relied on the Pooled Cohort Equations (PCEs), developed in 2013, to estimate a person’s 10-year risk of atherosclerotic cardiovascular disease (ASCVD). But medical science e...

Dear Colleagues!  Today is Pharma Veterans Blog Post #183. Pharma Veterans shares the wealth of knowledge and wisdom of Veterans for the benefit of entire Pharma Community. It aims to recognize and celebrate the Pharma Industry Professionals.  Pharma Veterans Blog  is published by Asrar Qureshi on WordPress , the top blog site.  If you wish to share your stories, ideas and thoughts, please email to asrar@asrarqureshi.com for publishing your contributions here . Continued from Previous…… Current Recommendations for Statin Therapy In the last 6 parts, I have walked you through the statins’ controversy, its basis, its protagonists and antagonists. There is no doubt that there are powerful voices on both sides of the disputes. There is equally no doubt that commercial interests are, at times, likely to prevail upon academic purity. It all relates to money, and there is a lot of money in statins. People can easily get killed where money prev...